Document Detail

Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha.
MedLine Citation:
PMID:  20127943     Owner:  NLM     Status:  MEDLINE    
A large body of evidence suggests that the platelet-derived growth factor (PDGF) family and associated receptors are potential targets in oncology therapeutic development because of their critical roles in the proliferation and survival of various cancers and in the regulation and growth of the tumor stroma and blood vessels. Several small molecules that nonspecifically target the PDGF signaling axis are in current use or development as anticancer therapies. However, for the majority of these agents, PDGF and its receptors are neither the primary targets nor the principal mediators of anticancer activity. IMC-3G3, a fully human monoclonal antibody of the immunoglobulin G subclass 1, specifically binds to the human PDGF receptor alpha (PDGFRalpha) with high affinity and blocks PDGF ligand binding and PDGFRalpha activation. The results of preclinical studies and the frequent expression of PDGFRalpha in many types of cancer and in cancer-associated stroma support a rationale for the clinical development of IMC-3G3. Currently, IMC-3G3 is being evaluated in early clinical development for patients with several types of solid malignancies.
Gaurav D Shah; Nick Loizos; Hagop Youssoufian; Jonathan D Schwartz; Eric K Rowinsky
Related Documents :
16402903 - The proteasome and proteasome inhibitors in cancer therapy.
25184473 - Occupational therapy use by older adults with cancer.
1408193 - Hereditary and environmental factors associated with risk and progression of head and n...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cancer     Volume:  116     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-10     Completed Date:  2010-04-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1018-26     Citation Subset:  AIM; IM    
Copyright Information:
(c) 2010 American Cancer Society.
ImClone Systems Corporation, 33 ImClone Drive, Branchburg, NJ 08876, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use*
Drug Delivery Systems
Drug Design
Immunoglobulin G / therapeutic use
Neovascularization, Pathologic / drug therapy
Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors*,  immunology,  physiology
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/IMC-3G3; 0/Immunoglobulin G; EC, Platelet-Derived Growth Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Demand-specific alteration of medial prefrontal cortex response during an inhibition task in recover...
Next Document:  Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibod...